Download Files:
CCT245737
$95 – $750
Products Details
Product Description
– CCT245737 is an orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM.
Web ID
– HY-18958
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C16H16F3N7O
References
– [1]Osborne JD, et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J Med Chem. 2016 Jun 9;59(11):5221-37.|[2]Walton MI, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma.
CAS Number
– 1489389-18-5
Molecular Weight
– 379.34
Compound Purity
– 99.35
SMILES
– FC(F)(F)C(C=NC(NC1=CN=C(C#N)C=N1)=C2)=C2NC[C@H]3CNCCO3
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 32 mg/mL
Target
– Checkpoint Kinase (Chk)
Isoform
– Chk1;Chk2
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
